Skip to main content
. 2018 Nov 6;37:268. doi: 10.1186/s13046-018-0930-0

Fig. 8.

Fig. 8

miR-31-5p prevents nuclear location of PARP1 in vivo. a-b The volumes of tumor in Oxaliplatin -treated group were significant smaller than that in control group, *P<0.05 vs control at day 21. c Western blot supports the results consistent with cells. d-e Histoflorescence and immunohistochemical indicated that the miR-31-5p may prevent the nuclear localization of PARP1